Audentes Therapeutics Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Audentes Therapeutics's estimated annual revenue is currently $26.7M per year.
- Audentes Therapeutics received $172.5M in venture funding in October 2018.
- Audentes Therapeutics's estimated revenue per employee is $98,376
- Audentes Therapeutics's total funding is $212.5M.
- Audentes Therapeutics has 271 Employees.
- Audentes Therapeutics grew their employee count by 23% last year.
- Audentes Therapeutics currently has 43 job openings.
|Donald Wuchterl||Senior Vice President of Technical Operations|
|Eric Mosbrooker||SVP & Chief Commercial Officer|
|Nick Grundy||Director of IT|
|Suyash Prasad||Chief Medical Officer and Senior Vice President|
|Natalie Holles||President and Chief Operating Officer|
|Mary Newman||SVP/Regulatory Affairs|
|John Gray||SVP/Chief Scientific Officer|
|Steven Terry||Director of Facilities Management|
|Helga Stockton||Vice President, Quality|
|Emma James||Senior Director, Medical Affairs and Health Outcomes|
What Is Audentes Therapeutics?
Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities. If you are interested in learning more about our company, please do not hesitate to contact us.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%||N/A|
|Full Spectrum A...||$6M||42||5%||N/A|
Audentes Therapeutics News
SAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company ...
In trading on Wednesday, shares of Audentes Therapeutics Inc (Symbol: BOLD) entered into oversold territory, hitting an RSI reading of 28.9, ...
On Thursday, shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) marked $31.02 per share versus a previous $29.62 closing price.
Audentes Therapeutics Funding
|2013-07-22||$30.0M||A||OrbiMed Advisors, 5AM Ventures||Article|
|2018-01-24||$172.5M||Undisclosed||BofA Merrill Lynch||Article|
|2018-01-26||$231.4M||Undisclosed||BofA Merrill Lynch||Article|
|2018-10-10||$172.5M||Undisclosed||BofA Merrill Lynch||Article|
Audentes Therapeutics Executive Hires
|2014-03-05||Suyash Prasad||SVP/Chief Medical Officer||Article|
|2017-05-09||John Gray||SVP/Chief Scientific Officer||Article|
|2017-07-19||Fulvio Mavilio||VP scientific affairs, Europe||Article|
|2018-05-09||Natalie Holles||President/Chief Operating Officer||Article|
|2019-01-04||Eric Mosbrooker||SVP/Chief Commercial Officer||Article|